Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01963715 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors
A Phase 1 study, sponsored by ImmunoGen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT01963715 is a Phase 1 study that was terminated before completion, run by ImmunoGen. The registered enrollment target is 20 participants.
The verdict
NCT01963715, a Phase 1 study, was terminated before completion, sponsored by ImmunoGen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a Phase 1, first-in-human study to determine the recommended dose of IMGN289 in adult patients with advanced EGFR-positive tumors.
Interventions
- DRUG IMGN289
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2013-10 |
| Est. Completion | 2015-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01963715
The ClinicalTrials.gov registry entry for NCT01963715 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ImmunoGen, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IMGN289 is the first listed.
NCT01963715 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01963715 about?
NCT01963715 is a clinical study titled "A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors". This is a Phase 1, first-in-human study to determine the recommended dose of IMGN289 in adult patients with advanced EGFR-positive tumors.
What is the current status of trial NCT01963715?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2013-10. Estimated completion is 2015-04.
What interventions are being tested in trial NCT01963715?
The interventions under investigation include: IMGN289 (DRUG).
Who is sponsoring clinical trial NCT01963715?
This trial is sponsored by ImmunoGen, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.